Coenzyme Q-10 reduced the aberrant production of extracellular matrix proteins in uterine leiomyomas through transforming growth factor beta 3
article
OA: gold
CC0
Abstract
OBJECTIVE: To evaluate the impact of coenzyme Q-10 (CoQ-10) on the dysregulated synthesis of extracellular matrix proteins mediated by transforming growth factor beta 3 (TGF-β3) in uterine leiomyomas. DESIGN: Laboratory study. SETTING: University. PATIENTS: None. INTERVENTIONS: Treatment of immortalized uterine myometrial and leiomyoma cells to TGF-β3 and CoQ-10. MAIN OUTCOME MEASURES: The protein concentrations of collagen 1A1 (COL1A1), collagen 3A1 (COL3A1), collagen 11A1 (COL11A1), and fibronectin (FN1) were assessed through western blot analysis after treatment of immortalized uterine myometrial and leiomyoma cells with both transforming growth factor beta (TGF-β) 3 and concentrations of CoQ-10 at 10, 50, and 100 μM concurrently for 24 hours. RESULTS: Immortalized uterine leiomyoma and myometrial cells exposed to TGF-β3 for 24 hours demonstrated a significant up-regulation of COL1A1, COL3A1, COL11A1, and FN1 compared with untreated cells. In leiomyoma cells, concurrent treatment with CoQ-10 over the same timeframe revealed a dose-dependent decrease in these protein concentrations compared with those in cells treated with TGF-β3 alone. At the highest concentration of 100 μM of CoQ-10, significant decreases in the amounts of COL1A1 (0.59 ± 0.10-fold), COL3A1 (0.46 ± 0.09-fold), COL11A1 (0.53 ± 0.09-fold), and FN1 (0.56 ± 0.09-fold) were observed. Similarly, myometrial cells exposed to both TGF-β3 and CoQ-10 demonstrated a dose-responsive decline in the amount of extracellular matrix protein compared with cells exposed to TGF-β3 alone. Significant reductions in the amounts of COL1A1 (0.75 ± 0.03-fold), COL3A1 (0.48 ± 0.06-fold), COL11A1 (0.38 ± 0.06), and FN1 (0.69 ± 0.04-fold) were appreciated at 100-μM CoQ-10. CONCLUSION: Coenzyme Q-10 mitigated the aberrant production of key biomarkers of the extracellular matrix mediated by TGF-β3 in uterine leiomyomas. Our findings highlight a promising nonhormonal compound that can counteract the fibroproliferative process inherent to leiomyomas.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
References (46)
- doi:10.1371/journal.pone.0215646 via openalex
- doi:10.1155/2018/2414609 via openalex
- doi:10.3390/ijms18112435 via openalex
- doi:10.1016/j.fertnstert.2012.07.1132 via openalex
- doi:10.1080/07315724.2001.10719063 via openalex
- doi:10.3390/nu14204383 via openalex
- doi:10.1016/j.biopha.2018.10.133 via openalex
- doi:10.1055/s-0030-1251475 via openalex
- doi:10.2119/molmed.2014.00053 via openalex
- doi:10.1016/j.fertnstert.2006.08.111 via openalex
- doi:10.1016/j.ajog.2005.12.059 via openalex
- doi:10.3945/ajcn.115.119834 via openalex
- doi:10.5468/ogs.2018.61.2.192 via openalex
- doi:10.3389/fonc.2022.925165 via openalex
- doi:10.1016/s0021-9258(17)35666-1 via openalex
- doi:10.2147/ijwh.s51083 via openalex
- doi:10.1152/ajplung.00163.2007 via openalex
- doi:10.1016/j.ajog.2011.12.002 via openalex
- doi:10.1177/1933719109343310 via openalex
- doi:10.1002/tox.22270 via openalex
- W6798839903 via openalex
- W6839971930 via openalex
- doi:10.1016/j.intimp.2022.108868 via openalex
- doi:10.1016/j.xcrp.2021.100515 via openalex
- doi:10.1177/0091270007307571 via openalex
- doi:10.1093/humupd/dmr031 via openalex
- doi:10.1016/j.fertnstert.2009.01.081 via openalex
- doi:10.1101/cshperspect.a004978 via openalex
- doi:10.1055/s-0037-1599090 via openalex
- doi:10.1055/s-0030-1251476 via openalex
- doi:10.1073/pnas.0808188105 via openalex
- doi:10.1038/sj.ki.5000054 via openalex
- doi:10.1155/2019/8039694 via openalex
- doi:10.1021/bi500647d via openalex
- doi:10.1055/s-2004-828614 via openalex
- doi:10.1016/j.fertnstert.2018.12.026 via openalex
- doi:10.1111/j.1365-2265.2008.03207.x via openalex
- doi:10.1016/s0015-0282(00)00418-0 via openalex
- doi:10.1093/humupd/dmx032 via openalex
- doi:10.1053/jhep.2002.32673 via openalex
- doi:10.1007/978-3-030-25650-0_6 via openalex
- doi:10.1016/j.fertnstert.2014.03.042 via openalex
- doi:10.1016/j.intimp.2020.107347 via openalex
- doi:10.1258/000456303321610493 via openalex
- doi:10.1016/j.taap.2009.07.030 via openalex
- doi:10.18632/oncotarget.21247 via openalex
Source provenance
- openalex
- last seen: 2026-05-13T19:29:15.267004+00:00
License: CC0
· commercial use OK